Ask AI
ProCE Banner Activity

Optimizing Multidisciplinary Care of Immunotherapy-Eligible Patients With Newly Diagnosed Advanced NSCLC: Strategies for Rural and Community Practices

Slideset

These downloadable slides highlight biomarker-directed guidance for the management of newly diagnosed advanced NSCLC and practical considerations for immunotherapy as well as strategies to better equip patients and caregivers, with a focus on safety recommendations. 

Released: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Target Audience

This activity is intended for oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals caring for patients with newly diagnosed advanced/metastatic NSCLC in rural community cancer practices.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with newly diagnosed advanced/metastatic NSCLC at risk for health inequities due to access to care, race/ethnicity, age, or other sociodemographic factors

  • Implement best practices in molecular testing and interpreting results to identify every patient with newly diagnosed advanced/metastatic NSCLC eligible for immunotherapy

  • Collaborate with each patient and the multidisciplinary team to personalize an immunotherapy-based treatment plan for newly diagnosed advanced/metastatic NSCLC with consideration for the latest data, expert recommendations, and patient preferences

  • Educate all eligible patients and their caregivers on the risk–benefit profile and goals of immunotherapy-based treatment using effective communication strategies and resources

  • Manage immune-related adverse events associated with immunotherapy-based treatments to maximize quality of life and clinical outcomes in each patient with newly diagnosed advanced/metastatic NSCLC

  • Manage immune-related adverse events associated with immunotherapy-based treatments to maximize quality of life and clinical outcomes in each patient with newly diagnosed advanced/metastatic NSCLC